Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Robin T. Zon"'
Autor:
Mona N. Fouad, Marjorie J. Good, William J. Hicks, Robert L. Comis, Stephen S. Grubbs, Steven Joffe, Worta McCaskill-Stevens, Steven N. Wolff, Rebecca A. Enos, Afshin Dowlati, Michelle E. Duff, Ellen S. Richmond, Kevin P. Weinfurt, Michael A. Bookman, Patrick J. Loehrer, Robin T. Zon, Neal J. Meropol, Andrea Denicoff, Terrance L. Albrecht, Alan P. Lyss, Margo Michaels, Jean G. Ford, Lidia Schapira, Debra Wujcik, Derek Raghavan, David M. Dilts, Suanna S. Bruinooge, Peggy Devine
Publikováno v:
Journal of Oncology Practice. 9:267-276
Many challenges to clinical trial accrual exist, resulting in studies with inadequate enrollment and potentially delaying answers to important scientific and clinical questions.The National Cancer Institute (NCI) and the American Society of Clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c4b7b2e3ca54a3aa05e5be92cfc3bda
https://doi.org/10.1200/jop.2013.001119
https://doi.org/10.1200/jop.2013.001119
Autor:
Eileen P. Dimond, Robin T. Zon, Bryan J. Weiner, Diane St. Germain, Andrea M. Denicoff, Kandie Dempsey, Angela C. Carrigan, Randall W. Teal, Marjorie J. Good, Worta McCaskill-Stevens, Stephen S. Grubbs
QUESTION ASKED: Is there a tool for sites engaged in cancer clinical research to use to assess their infrastructure and improve their research conduct toward exemplary levels of performance beyond the standard of Good Clinical Practice (GCP)? SUMMARY
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd0149a1c86513ec4294c2af8af4c565
https://europepmc.org/articles/PMC4976452/
https://europepmc.org/articles/PMC4976452/
Publikováno v:
Journal of Clinical Oncology. 16:1294-1297
PURPOSE To determine the therapeutic results in advanced germ cell tumor (GCT) patients with initial human chorionic gonadotropin (hCG) elevation greater than 50,000 mIU/mL and to document the levels of hCG decline and subsequent plateau and outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba1362f45579800bf6092821cda78f44
https://doi.org/10.1200/jco.1998.16.4.1294
https://doi.org/10.1200/jco.1998.16.4.1294
Autor:
Judy Garber, Elizabeth Goss, Mark E. Robson, Barnett S. Kramer, Powel H. Brown, Robin T. Zon, Victor G. Vogel, Dana S. Wollins, Ismail Jatoi, Rowan T. Chlebowski
Oncologists have a critical opportunity to utilize risk assessment and cancer prevention strategies to interrupt the initiation or progression of cancer in cancer survivors and individuals at high risk of developing cancer. Expanding knowledge about
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a286cbfe47a1a7e8e5e01cf031a973de
https://europepmc.org/articles/PMC2668639/
https://europepmc.org/articles/PMC2668639/
Autor:
Rafat Ansari, Robin T. Zon, John McClean, Joel Picus, Alan B. Sandler, Stephen D. Williams, Douglas Helman, Patrick J. Loehrer
Publikováno v:
Investigational new drugs. 19(3)
Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m2 days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were the most
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1a5cdc799cb4d4c705ab86e3ff7f601
https://pubmed.ncbi.nlm.nih.gov/11561679
https://pubmed.ncbi.nlm.nih.gov/11561679